Opdivo for Head and Neck
Nivolumab is FDA approved for head and neck cancer. In the seminal NEJM study, among patients with platinum-refractory, recurrent squamous-cell carcinoma of the head and neck, treatment with nivolumab resulted in longer overall survival than treatment with standard, single-agent therapy. OPDIVO is indicated for the treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) with disease progression on or after platinum-based therapy.
Robert L. Ferris, M.D., Ph.D., George Blumenschein, Jr., M.D., Jerome Fayette, M.D., Ph.D., Joel Guigay, M.D., A. Dimitrios Colevas, M.D., Lisa Licitra, M.D., Kevin Harrington, Ph.D., F.R.C.P., F.R.C.R., Stefan Kasper, M.D., Everett E. Vokes, M.D., Caroline Even, M.D., Francis Worden, M.D., Nabil F. Saba, M.D., Lara C. Iglesias Docampo, M.D., Robert Haddad, M.D., Tamara Rordorf, M.D., Naomi Kiyota, M.D., Ph.D., Makoto Tahara, M.D., Ph.D., Manish Monga, M.D., Mark Lynch, Ph.D., William J. Geese, Ph.D., Justin Kopit, Ph.D., James W. Shaw, Pharm.D., Ph.D., M.P.H., and Maura L. Gillison, M.D., Ph.D., Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med 2016; 375:1856-1867
Opdivo Prescribing Information 2017